Limula has unveiled LimONE, a disruptive cell therapy manufacturing solution that automates complex and fragmented processes into a seamless workflow. Through consolidation of multiple unit operations into a single closed consumable, LimONE enables end-to-end production of these highly personalised treatments—reducing labour, equipment, and infrastructure costs while ensuring process standardisation and scalability. LimONE was officially presented by Luc Henry, CEO of Limula at Advanced Therapies Week in Dallas, Texas, on January 22, 2025, during the Innovation Zone Tech Spotlight Session.
LimONE is designed for both hospitals and biopharma companies alike, providing a versatile tool that supports the production of multiple types of cell therapy, including CAR-T and gene-edited hematopoietic stem cells. Using the exact same single use consumable at all stages of therapeutic development eliminates lengthy technology transfer that often delays the start of clinical trials by months. As a result, LimONE empowers cell therapy developers to accelerate the transition from research and development through clinical trials leading to commercialisation.
Limula have combined ‘Swiss Made’ precision engineering and Cell and Gene Therapy expertise to build a product that meets the most stringent user requirements. They partnered with Stockholm-based industrial design firm Fjaryl to incorporate input from over 20 academic and industry experts into key design choices following a series of in-person feedback sessions held at the company location in Lausanne, Switzerland.
